NCT05008861Unknown1 期
Safety of Gut Microbiota Reconstruction Plus PD-1/PD-L1 Monoclonal Antibodies to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Incidence of anti-PD-1/PD-L1-related Adverse Events
研究概览
简要总结
In this study, patients with locally advanced or metastatic NSCLC after first-line treatment with PD-1/PDL-1 monoclonal antibody will be treated with Gut Microbiota reconstruction(such as FMT) combined with PD-1/PDL-1 monoclonal antibody. We will evaluate the safety of FMT in the treatment of advanced NSCLC, and analyze the effect of FMT on intestinal flora and immunophenotype of patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Volunteer to participate in this trial, fully understand this trial, and sign the Informed Consent Form (ICF).
- •2.18-75 years old on the day of signing the ICF. 3.Locally advanced/metastatic non-small cell lung cancer diagnosed by histology or cytology. no epidermal growth factor receptor (EGFR) sensitive mutations, anaplastic lymphoma kinase (ALK) gene rearrangement, ROS Proto-oncogene 1 (ROS1) gene fusion.
- •4.Have stable disease (SD) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after receive at least 2 doses of anti-PD-1/PD-L1 for first-line treatment.
- •5.Have not received systemic treatment for locally advanced/metastatic NSCLC before immunotherapy.
- •6.Have measurable target lesions judged by the investigator according to Response Evaluation Criteria In Solid Tumors (RECIST V1.1).
- •7.0~1 ECOG score. 8.Life expectancy ≥ 12 weeks. 9.Have sufficient organ function, evaluated based on blood routine, renal function, liver function, and coagulation laboratory test results (and have not received blood transfusion or infusion of apheresis components within 14 days before the study drug administration , Erythropoietin, granulocyte colony stimulating factor and other medical support treatments).
- •10.Women of Childbearing Potential (WOBCP) must undergo a serum pregnancy test within 7 days before the first medication, and the result is negative; WOBCP or men and their WOBCP partners should agree from signing the ICF to the last one. Take effective contraceptive measures within 6 months after taking the study drug.
排除标准
- •Before the first administration of the anti-PD-1/PD-L1 reatment: a) have received previous systemic cytotoxic chemotherapy for metastatic disease; b) have received other targeted or biological anti-tumor therapy for metastatic disease ; c) received major surgery (<3 weeks before the first dose); d) received lung radiotherapy >30 Gy within 6 months before the first dose of the trial treatment; e) the first trial treatment Palliative radiotherapy was completed within 7 days before administration.
- •Any other form of anti-tumor therapy is expected during the study period.
- •Have progressive disease (PD) or response(CR or PR) defined by RECIST v1.1 after receive at least 2 doses of anti-PD-1/PD-L1 for first-line treatment.
- •Unable to tolerate anti-PD-1/PD-L1 treatment due to adverse events or other reasons.
- •Unable to swallow FMT capsules.
- •Received antibiotic treatment within 30 days before the planned FMT started.
- •Fecal occult blood test or calprotectin positive; have ulcerative colitis, Crohn's disease, ischemic enteritis, infectious enteritis, etc not suitable to take intestinal bacteria capsules, but not include anti-PD-1/PD-L1-related colitis.
- •Live virus vaccines have been vaccinated within 30 days before the planned treatment. Seasonal influenza vaccine without live virus is allowed.
- •A history of past malignant disease is known, unless the subject receives potentially curative treatment and there is no evidence of disease recurrence within 5 years after starting treatment.
- •Accompanying known active central nervous system (CNS) metastasis and/or cancerous meningitis.
- •According to the standard of Common Adverse Event Terminology (CTCAE) 4th edition, peripheral neuropathy has been ≥2 grade.
- •Severe hypersensitivity reactions to other monoclonal antibody treatments have occurred in the past.
- •Accompanied by active autoimmune diseases, systemic treatment (ie, use of disease modifiers, corticosteroids or immunosuppressive drugs) is required within the past 2 years.
- •Are receiving long-term systemic steroid therapy. Subjects with asthma who require intermittent use of bronchodilators, inhaled steroids, or topical steroid injections are not excluded.
- •Have received any other anti-PD-1 or PD-L1 or PD-L2 drugs or antibodies in the past, or small molecule therapy that targets other immunomodulatory receptors or mechanisms. Participated in any other anti-PD-1/PD-L1 trials and received anti-PD-1/PD-L1 treatment. Such antibodies include (but are not limited to) antibodies against IDO, PD-L1, IL-2R and GITR.
- •Active infections requiring treatment.
- •Known human immunodeficiency virus (HIV) history (known HIV1/2 antibody positive). Accompanied by known active hepatitis B or C.
- •Being pregnant or breastfeeding, or expecting to conceive or conceive during the period of study drug treatment and within the required contraceptive period after the last administration of the study drug.
- •The researcher believes that there are any circumstances that are not suitable for selection.
研究组 & 干预措施
FMT with anti-PD-1/PD-L1 treatment
Experimental
干预措施: Capsulized Fecal Microbiota Transplant (Procedure)
FMT with anti-PD-1/PD-L1 treatment
Experimental
干预措施: Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody (Drug)
FMT with anti-PD-1/PD-L1 treatment
Experimental
干预措施: Platinum based chemotherapy (Drug)
结局指标
主要结局
Incidence of anti-PD-1/PD-L1-related Adverse Events
时间窗: 2 years
Number of patients with adverse events related to anti-PD-1/PD-L1 after FMT
Incidence of FMT-related Adverse Events
时间窗: 2 years
Number of patients with adverse events after FMT
次要结局
- Changes in diversity and composition of gut microbiota(2 years)
- Changes in concentration of peripheral blood mononuclear cells(2 years)
- Objective response rate (ORR)(2 years)
- Changes in concentration of tumor immune related cytokines(2 years)
- Efficiency of FMT engraftment(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerGastric CancerNCT06253611GERCOR - Multidisciplinary Oncology Cooperative Group120
招募中
不适用
MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns]Melanoma, SkinMelanoma Stage IiiNCT06299878Russian Academy of Medical Sciences72
尚未招募
3 期
PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial.Nasopharyngeal CarcinomaNCT06486220Yun-fei Xia96
招募中
不适用
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)NSCLC Stage IVNSCLC, RecurrentNCT04636775Jun Zhang, MD, PhD46
终止
2 期
Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer PatientsNon Small Cell Lung CancerNCT04880382Institut Bergonié8